BRPI0512161A - métodos para tratar e prevenir um distúrbio paroxìsmico em um animal adulto ou jovem, para aumentar o limite de ataques no cérebro ou tecido neural de um animal, para tratar e evitar dor em um animal e para reduzir surto epiléptico em células cerebrais, e, composição farmacêutica - Google Patents

métodos para tratar e prevenir um distúrbio paroxìsmico em um animal adulto ou jovem, para aumentar o limite de ataques no cérebro ou tecido neural de um animal, para tratar e evitar dor em um animal e para reduzir surto epiléptico em células cerebrais, e, composição farmacêutica

Info

Publication number
BRPI0512161A
BRPI0512161A BRPI0512161-2A BRPI0512161A BRPI0512161A BR PI0512161 A BRPI0512161 A BR PI0512161A BR PI0512161 A BRPI0512161 A BR PI0512161A BR PI0512161 A BRPI0512161 A BR PI0512161A
Authority
BR
Brazil
Prior art keywords
animal
brain
methods
attacks
adult
Prior art date
Application number
BRPI0512161-2A
Other languages
English (en)
Inventor
Steven M Kriegler
Avtar S Roopra
Thomas P Sutula
Carl E Stafstrom
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of BRPI0512161A publication Critical patent/BRPI0512161A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MéTODOS PARA TRATAR E PREVENIR UM DISTúRBIO PAROXìSMICO EM UM ANIMAL ADULTO OU JOVEM, PARA AUMENTAR O LIMITE DE ATAQUES NO CéREBRO OU TECIDO NEURAL DE UM ANIMAL, PARA TRATAR E EVITAR DOR EM UM ANIMAL E PARA REDUZIR SURTO EPILéPTICO EM CéLULAS CEREBRAIS, E, COMPOSIçãO FARMACêUTICA A invenção refere-se a métodos para aliviar distúrbios paroxísmicos em um animal, particularmente epilepsia, pela modulação de glicólise em células cerebrais.
BRPI0512161-2A 2004-06-17 2005-06-17 métodos para tratar e prevenir um distúrbio paroxìsmico em um animal adulto ou jovem, para aumentar o limite de ataques no cérebro ou tecido neural de um animal, para tratar e evitar dor em um animal e para reduzir surto epiléptico em células cerebrais, e, composição farmacêutica BRPI0512161A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58043604P 2004-06-17 2004-06-17
PCT/US2005/021845 WO2006002121A2 (en) 2004-06-17 2005-06-17 Compounds and methods for treating seizure and paroxysmal disorders

Publications (1)

Publication Number Publication Date
BRPI0512161A true BRPI0512161A (pt) 2008-02-12

Family

ID=35427194

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512161-2A BRPI0512161A (pt) 2004-06-17 2005-06-17 métodos para tratar e prevenir um distúrbio paroxìsmico em um animal adulto ou jovem, para aumentar o limite de ataques no cérebro ou tecido neural de um animal, para tratar e evitar dor em um animal e para reduzir surto epiléptico em células cerebrais, e, composição farmacêutica

Country Status (11)

Country Link
US (1) US7795227B2 (pt)
EP (1) EP1885379B1 (pt)
JP (1) JP2008502705A (pt)
KR (1) KR20070034591A (pt)
CN (1) CN1972697A (pt)
AU (2) AU2005258021B2 (pt)
BR (1) BRPI0512161A (pt)
CA (1) CA2571055C (pt)
ES (1) ES2590259T3 (pt)
IL (1) IL179864A0 (pt)
WO (1) WO2006002121A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20090252834A1 (en) * 2004-05-10 2009-10-08 Michael Griffin Hayek Compositions comprising glucose anti-metabolites
KR20070034591A (ko) 2004-06-17 2007-03-28 위스콘신 얼럼나이 리서어치 화운데이션 발작 및 발작병을 치료하기 위한 화합물 및 방법
EP1871881A2 (en) * 2005-02-14 2008-01-02 Wisconsin Alumni Research Foundation Metabolic-based methods for modulating gene expression
US20060217303A1 (en) * 2005-03-25 2006-09-28 Wisconsin Alumni Research Foundation Compounds and Methods for Treating Seizure Disorders
DK1880001T3 (da) 2005-05-31 2011-09-12 Iams Company Feline probiotiske lactobacilli
WO2006130188A1 (en) 2005-05-31 2006-12-07 The Iams Company Feline probiotic bifidobacteria
US20060287253A1 (en) * 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
US20080089981A1 (en) * 2006-10-17 2008-04-17 N.V. Nutricia Ketogenic diet
US20100222304A1 (en) 2006-11-02 2010-09-02 Lillian W Chiang Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis
JP5799299B2 (ja) * 2007-02-01 2015-10-21 ザ・アイムス・カンパニーＴｈｅ Ｉａｍｓ Ｃｏｍｐａｎｙ ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法
RU2429853C2 (ru) * 2007-02-01 2011-09-27 Дзе Иамс Компани Способ уменьшения воспаления и окислительного стресса у млекопитающих
WO2009140624A2 (en) 2008-05-16 2009-11-19 Takeda San Diego, Inc. Glucokinase activators
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8236768B2 (en) 2008-10-03 2012-08-07 3B Pharmaceuticals, Inc. Topical antiviral formulations
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
AU2011285703B2 (en) * 2010-08-04 2016-03-10 Wisconsin Alumni Research Foundation Methods and pharmaceutical compositions for treating adverse or deleterious sequellae of traumatic brain injury
JP5888746B2 (ja) * 2010-08-24 2016-03-22 国立大学法人 宮崎大学 マトリックスメタロプロテアーゼ活性抑制組成物
US10668041B2 (en) 2014-12-08 2020-06-02 Societe Des Produits Nestle Sa Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
RU2712942C2 (ru) 2014-12-08 2020-02-03 Сосьете Де Продюи Нестле С.А. Композиции и способы, включающие триглицериды со средней длиной цепи, для лечения эпилепсии
CN106668035A (zh) * 2017-01-24 2017-05-17 中南大学湘雅三医院 一种抗癫痫药物组合物
CN115884766A (zh) * 2020-05-29 2023-03-31 睿升公司 用于使用中链甘油三酯治疗婴儿痉挛的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08511041A (ja) * 1993-03-31 1996-11-19 ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルバニア 哺乳動物生組織の増殖に作用する方法、及びそのための化合物ならびに組成物
US5643883A (en) * 1995-01-19 1997-07-01 Uab Research Foundation Glucose-6-phosphate uptake inhibitors and novel uses thereof
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US6620850B2 (en) * 2001-09-19 2003-09-16 University Of Florida Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors
US7145032B2 (en) * 2002-02-23 2006-12-05 Washington University Therapeutic malonic acid/acetic acid C60 tri-adducts of buckminsterfullerene and methods related thereto
RU2005125428A (ru) 2003-01-10 2006-03-10 Тресхолд Фармасьютикалз, Инк. (Us) Лечение рака 2-деоксиглюкозой
KR20050098244A (ko) 2003-01-10 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 2-데옥시글루코오스를 사용한 암 치료 방법
CN1771043A (zh) 2003-01-10 2006-05-10 施瑞修德制药公司 利用2－脱氧葡萄糖治疗癌症
RU2005126042A (ru) 2003-01-17 2006-02-27 Тресхолд Фармасьютикалз, Инк. (Us) Лечение доброкачественной гиперплазии простаты
AU2004206870A1 (en) 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Treatment of benign prostatic hyperplasia using energolytic agents
US20060172953A1 (en) * 2003-01-17 2006-08-03 Threshold Pharmaceuticals Inc. Treatment of benign prostatic hyperplasia using energolytic agents
KR20070034591A (ko) 2004-06-17 2007-03-28 위스콘신 얼럼나이 리서어치 화운데이션 발작 및 발작병을 치료하기 위한 화합물 및 방법
WO2006024489A2 (en) 2004-08-30 2006-03-09 Interstitial Therapeutics Methods and compositions for the treatment of cell proliferation
GB0419990D0 (en) 2004-09-09 2004-10-13 Suisse Electronique Microtech Marking articles
EP1871881A2 (en) 2005-02-14 2008-01-02 Wisconsin Alumni Research Foundation Metabolic-based methods for modulating gene expression
US20060217303A1 (en) * 2005-03-25 2006-09-28 Wisconsin Alumni Research Foundation Compounds and Methods for Treating Seizure Disorders
US20060287253A1 (en) * 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders

Also Published As

Publication number Publication date
KR20070034591A (ko) 2007-03-28
IL179864A0 (en) 2007-07-04
CA2571055C (en) 2011-11-29
EP1885379A2 (en) 2008-02-13
EP1885379B1 (en) 2016-07-20
US20060088517A1 (en) 2006-04-27
AU2005258021A1 (en) 2006-01-05
CA2571055A1 (en) 2006-01-05
AU2009201069A1 (en) 2009-04-09
ES2590259T3 (es) 2016-11-21
WO2006002121A2 (en) 2006-01-05
JP2008502705A (ja) 2008-01-31
WO2006002121A3 (en) 2006-03-02
AU2005258021B2 (en) 2008-12-18
CN1972697A (zh) 2007-05-30
US7795227B2 (en) 2010-09-14

Similar Documents

Publication Publication Date Title
BRPI0512161A (pt) métodos para tratar e prevenir um distúrbio paroxìsmico em um animal adulto ou jovem, para aumentar o limite de ataques no cérebro ou tecido neural de um animal, para tratar e evitar dor em um animal e para reduzir surto epiléptico em células cerebrais, e, composição farmacêutica
WO2008011083A9 (en) Compounds for enhancing arginase activity and methods of use thereof
WO2006124913A3 (en) Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
CY1111359T1 (el) Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer
IL219857A0 (en) Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis
WO2004037204A3 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
WO2008157787A3 (en) Hydroxylated tolans and related compounds in the treatment of cancer
WO2011038210A3 (en) Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
BRPI0417493B8 (pt) uso de uma toxina botulínica para tratamento de distúrbios da pele
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
WO2007101002A3 (en) A novel non-selective cation channel in neuronal cells and methods for treating brain swelling
DE602006006068D1 (de) Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd
PH12019500177A1 (en) Treatment and prevention of sleep disorders
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2004015130A3 (en) Modulators of rabggt and methods of use thereof
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
WO2017190044A8 (en) Methods for detecting and treating pain using brain activity
IS8540A (is) Notkun TWEAK stilla og tálma til að meðhöndla taugasjúkdóma
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
van Luijtelaar Genetic models of absence epilepsy: new concepts and insights
WO2010018996A3 (ko) 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물
Kalita et al. Phonophobia and brainstem excitability in migraine
EA200702189A1 (ru) Способ лечения и профилактики диабета второго типа
WO2006101910A3 (en) Peptide compounds and methods of using peptide compounds to treat conditions affecting the cardiac, pulmonary, and nervous systems
WO2010036813A8 (en) Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2140 DE 10/01/2012.